Glükóz Pharmaregist (Glucose Monohydrate)

Glükóz Pharmaregist is a sterile intravenous solution containing glucose monohydrate as the active ingredient. It is supplied in a liquid form for injection, intended for use in clinical settings within the EU. The product provides an immediate source of glucose to support cellular energy metabolism when administered intravenously. It is packaged according to pharmaceutical standards for safe handling and administration and proper dosing by qualified healthcare professionals.

Glükóz Pharmaregist is used primarily to restore or maintain blood glucose levels in patients who cannot obtain adequate glucose orally or enterally.

- Treatment of hypoglycemia in emergency or perioperative settings. - Provision of caloric support during prolonged fasting or before surgery. - Dilution and carrier for compatible intravenous medications requiring a glucose base. - Support of metabolic needs in patients receiving parenteral nutrition. - Management of glucose deficits in critically ill or trauma patients. - Stabilization of blood glucose during diagnostic procedures that require sedation.

The safety profile of Glükóz Pharmaregist reflects the typical reactions associated with intravenous glucose administration.

Common: - Transient hyperglycemia that resolves with monitoring. - Mild irritation at the injection site. - Nausea or vomiting if administered rapidly. - Temporary electrolyte shifts, such as low potassium. - Mild headache during infusion.

Serious: - Severe hyperglycemia leading to osmotic diuresis. - Hypersensitivity reactions, including rash or anaphylaxis. - Fluid overload causing pulmonary edema. - Severe metabolic acidosis in patients with impaired glucose utilization.

When using Glükóz Pharmaregist, healthcare professionals should assess patient-specific factors and monitor relevant parameters to minimize risks.

- Verify blood glucose levels before and during infusion to avoid excessive hyperglycemia. - Adjust infusion rate in patients with renal or cardiac insufficiency to prevent fluid overload. - Use caution in individuals with known hypersensitivity to glucose solutions. - Monitor electrolytes, especially potassium, as rapid glucose infusion can shift serum levels. - Avoid concurrent administration with high‑dose insulin without appropriate glucose monitoring. - Consider alternative carbohydrate sources for patients with hereditary fructose intolerance.

Glükóz Pharmaregist may interact with other intravenous agents, requiring attention to compatibility and metabolic effects.

Avoid: - Co‑administration with hypertonic dextrose solutions that could cause severe hyperglycemia. - Mixing with calcium‑containing solutions that may precipitate calcium phosphate.

Use with caution: - Concurrent insulin therapy, which may increase the risk of rapid glucose fluctuations. - Electrolyte‑balancing agents such as potassium chloride, due to potential shifts in serum potassium. - Diuretics that affect fluid balance, as excess glucose can exacerbate dehydration.